Selective Activation of Somatostatin Receptor Subtypes Differentially Modulates Secretion and Viability in Human Medullary Thyroid Carcinoma Primary Cultures: Potential Clinical Perspectives | Zendy

Maria Chiara Zatelli | Zendy; Daniela Piccin | Zendy; Federico Tagliati | Zendy; Arianna Bottoni | Zendy; Andrea Luchin | Zendy; Cristina Vignali | Zendy; Angelo Margutti | Zendy; Marta Bondanelli | Zendy; Gian Carlo Pansini | Zendy; Maria Rosa Pelizzo | Zendy; Michael D. Culler | Zendy; Ettore C. degli Uberti | Zendy

Open Access

Selective Activation of Somatostatin Receptor Subtypes Differentially Modulates Secretion and Viability in Human Medullary Thyroid Carcinoma Primary Cultures: Potential Clinical Perspectives

Author(s) -

Maria Chiara Zatelli,

Daniela Piccin,

Federico Tagliati,

Arianna Bottoni,

Andrea Luchin,

Cristina Vignali,

Angelo Margutti,

Marta Bondanelli,

Gian Carlo Pansini,

Maria Rosa Pelizzo,

Michael D. Culler,

Ettore C. degli Uberti

Publication year - 2006

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2006-0334

Subject(s) - somatostatin receptor 2 , somatostatin receptor , somatostatin , endocrinology , medicine , somatostatin receptor 1 , agonist , lanreotide , chromogranin a , biology , receptor , cancer research , acromegaly , hormone , immunohistochemistry , growth hormone

Medullary thyroid carcinoma (MTC) is a rare tumor originating from thyroid parafollicular C cells. We previously demonstrated that somatostatin (SRIH) reduces cell growth in the human MTC cell line, TT, which expresses all SRIH receptor (SSTR) subtypes and responds differently to selective SSTR agonists.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research